Hepatology international · 2026
Tolvaptan for hyponatremia in patients with cirrhosis: a post hoc subgroup analysis of a multicenter, randomized, double-blind, placebo-controlled trial.
СтатьяРандомизированное исследованиеМногоцентровое исследованиеКлиническое исследование II фазыНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Yu, Wang Huifen, Cheng Jun, Ye Weijiang, Ding Huiguo, Deng Cunliang, Wang Guiqiang, Zhu Haihang, Chen Chengwei, Gong Guozhong, Zhang Dazhi, Xie Qing, Wan Mobin, Cai Xiong, Li Jun, Mao Qing, Chen Yongping, Niu Junqi, Wang Hao, Mao Yiming, Tian Yuwang, Xian Mingji, Kong Yuanyuan, Ma Hong, Ou Xiaojuan, Jia Jidong
Аннотация
OBJECTIVES: The objective of this study was to investigate the efficacy and safety of oral tolvaptan for hyponatremia in patients with cirrhosis in China.
PATIENTS AND METHODS: In this post hoc subgroup analysis of a phase 2 clinical trial of oral tolvaptan for hyponatremia due to cirrhosis, heart failure, and syndrome of inappropriate antidiuretic hormone secretion in China, patients with hyponatremia due to cirrhosis received placebo or tolvaptan for 7 days (15 mg titrated to 30 or 60 mg/day). The primary endpoint was the average daily change in serum sodium level from baseline to days 4 and 7.
RESULTS: We enrolled 131 patients (90 males, 41 females) with cirrhosis mainly due to CHB (70.2%). Compared with placebo (N = 65), the tolvaptan group (N = 66) showed a significantly greater daily increase in serum sodium from baseline through day 4 (3.99 ± 2.70 vs. 0.32 ± 2.45 mmol/L; p < 0.0001) and 7 (4.72 ± 2.94 vs. 0.67 ± 3.05 mmol/L; p < 0.0001). The time to normalization of serum sodium levels was significantly shorter in the tolvaptan group (p < 0.0001). The serum sodium normalization rates on days 4 and 7 in the tolvaptan group were 59.09% and 68.18%, respectively, versus 18.46% and 24.62% in placebo (p < 0.0001). Seven days after tolvaptan cessation, the serum sodium levels were comparable to the placebo group. Tolvaptan was generally well tolerated, and the most common adverse events were dry mouth and thirst.
CONCLUSIONS: This study demonstrates that short-term oral tolvaptan is effective and safe for hyponatremia in patients with cirrhosis in China.
PATIENTS AND METHODS: In this post hoc subgroup analysis of a phase 2 clinical trial of oral tolvaptan for hyponatremia due to cirrhosis, heart failure, and syndrome of inappropriate antidiuretic hormone secretion in China, patients with hyponatremia due to cirrhosis received placebo or tolvaptan for 7 days (15 mg titrated to 30 or 60 mg/day). The primary endpoint was the average daily change in serum sodium level from baseline to days 4 and 7.
RESULTS: We enrolled 131 patients (90 males, 41 females) with cirrhosis mainly due to CHB (70.2%). Compared with placebo (N = 65), the tolvaptan group (N = 66) showed a significantly greater daily increase in serum sodium from baseline through day 4 (3.99 ± 2.70 vs. 0.32 ± 2.45 mmol/L; p < 0.0001) and 7 (4.72 ± 2.94 vs. 0.67 ± 3.05 mmol/L; p < 0.0001). The time to normalization of serum sodium levels was significantly shorter in the tolvaptan group (p < 0.0001). The serum sodium normalization rates on days 4 and 7 in the tolvaptan group were 59.09% and 68.18%, respectively, versus 18.46% and 24.62% in placebo (p < 0.0001). Seven days after tolvaptan cessation, the serum sodium levels were comparable to the placebo group. Tolvaptan was generally well tolerated, and the most common adverse events were dry mouth and thirst.
CONCLUSIONS: This study demonstrates that short-term oral tolvaptan is effective and safe for hyponatremia in patients with cirrhosis in China.